Kymera: Kymera Therapeutics (KYMR) Moves 13.8% Higher: Will This Strength Last?
Kymera Therapeutics (KYMR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Read full article »
Kymera is a Massachusetts-based biopharmaceutical company that develops targeted protein degradation therapies for the treatment of cancer and inflammatory diseases.
Read more